Boehringer Ingelheim To Break Into Biologics Contract Manufacturing Market In China
This article was originally published in PharmAsia News
Reporting 32% growth in China for 2012, BI will be the first Big Pharma to enter the biologics contract manufacturing space in the country.
You may also be interested in...
AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.